Black survivors of multiple myeloma say the latest developments in treatment give them hope even as federal research cuts ...

Multiple myeloma survivor Ronald D. Chin, one of CURE’s contributing bloggers, shared a bit of his blood cancer journey in a ...

The study tests two interventions: Elranatamab, a BCMA-CD3 bispecific antibody administered via injection, and Lenalidomide, an oral immunomodulatory drug. The goal is to determine which treatment ...

The FDA has approved Blenrep with BVd as a third-line treatment for relapsed or refractory multiple myeloma.

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Marc S. Raab, MD, PhD, discusses the different ways that combination therapy that includes teclistamab can benefit patients ...

The FDA approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of certain ...

Phung explained that prior response often guides selection: Patients who respond poorly to frontline therapy may move to CAR ...

GSK has received approval from the US Food and Drug Administration (FDA) for Blenrep (belantamab mafodotin-blmf) in ...

Mayor David Wortman announced late Tuesday that he has been diagnosed with multiple myeloma — though the diagnosis isn’t ...

The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market ...

The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.